United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 6, 2023, is available on Newsweek’s website, and recognizes the top 600 most responsible companies in the United States, spanning 14 industries.

America’s Most Responsible Companies were selected based on publicly available key performance indicators derived from Corporate Social Responsibility Reports and Sustainability Reports, as well as an independent survey asking U.S. residents about their perception of company activities related to corporate social responsibility. The key performance indicators focused on company performance in the environmental, social, and corporate governance areas, while the independent survey asked U.S. citizens about their perception of company activities related to corporate social responsibility.

United Therapeutics’ 2023 Corporate Responsibility and Public Benefit Report can be found at corporateresponsibility.unither.com.

“Maintaining the trust of all our stakeholders – our shareholders, patients, employees, and the communities in which we live and work – is core to our purpose and success,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics Corporation. “We are honored to be named among America’s Most Responsible Companies by Newsweek and Statista again this year, which reinforces our efforts as a public benefit corporation to operate responsibly and as a careful steward of all of our capital – human, natural, and financial.”

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun; we do good. We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of December 7, 2023 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231207991712/en/